On August 29, 2022 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported that it will host a webcast and conference call to provide a clinical and corporate update on Monday, September 12, 2022 (Press release, Cardiff Oncology, AUG 29, 2022, View Source,-2022 [SID1234618736]). The event will feature discussions on the planned development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer and updates on other development programs. In addition, company management will provide data updates from ongoing clinical trials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A replay of the webcast will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion.
Cardiff Oncology management will also participate in two upcoming investor conferences in New York.
The Baird Global Healthcare Conference on September 13th
The H.C. Wainwright 24th Annual Global Investment Conference on September 14th.
Conference details will be made available in the coming weeks.